Literature DB >> 11081197

Distribution and regulation of proconvertases PC1 and PC2 in human pituitary adenomas.

L Jin1, E Kulig, X Qian, B W Scheithauer, W F Young, D H Davis, N G Seidah, M Chretien, R V Lloyd.   

Abstract

Pituitary adenomas are members of the family of neuroendocrine cells and tumors which have secretory granules containing chromogranins/secretogranins and other proteins. Pituitary adenomas express the neuroendocrine specific proconvertases PC1 (also known as PC3) and PC2, which are important for the proteolytic processing of chromogranins/secretogranins molecules. We examined the distribution of PC1 and PC2 in primary cultures of 20 pituitary adenomas and analyzed the regulation of the proconvertase mRNAs and proteins by various secretagogues including hypothalamic hormones and phorbol ester to determine the role of PC1 and PC2 in CgA processing in pituitary adenomas. Although PC2 was present in all adenomas, there was a differential distribution of PC1 with PRL adenomas expressing lower levels of PC1 compared to other adenoma types by RT-PCR analysis, in situ hybridization and immunostaining. Treatment of primary cultures of pituitary adenomas with phorbol 12-myristrate 13-acetate (PMA) resulted in an increase in pancreastatin (PST) secretion in most pituitary adenomas and increased PC1 mRNA and protein expression in gonadotroph adenomas, but not in other types of adenomas. Analysis of a human pituitary adenoma cell line, immortalized by recombinant defective adenovirus (HP75), which expressed chromogranin A, FSH, PC1 and PC2 showed that PST was secreted by these immortalized cells. Treatment with TGF beta 1 resulted in an increase in PST secretion and in PC1 mRNA and protein. These results indicate that a) there is a differential distribution of PC1 in human pituitary adenomas with PRL adenomas expressing very little PC1 mRNA and protein and b) that PC1 expression in gonadotropin hormone-producing adenomas is regulated by PMA and TGF beta 1. These findings support the observation that chromogranin A is a substrate for the endoproteinase PC1 in human pituitary adenoma cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11081197     DOI: 10.1023/a:1009909232243

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  28 in total

1.  Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion.

Authors:  K Tatemoto; S Efendić; V Mutt; G Makk; G J Feistner; J D Barchas
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

2.  Different degrees of processing of secretogranin II in large dense core vesicles of bovine adrenal medulla and sympathetic axons correlate with their content of soluble PC1 and PC2.

Authors:  C Egger; R Kirchmair; R Hogue-Angeletti; R Fischer-Colbrie; H Winkler
Journal:  Neurosci Lett       Date:  1993-09-03       Impact factor: 3.046

3.  Pro-protein convertases of subtilisin/kexin family.

Authors:  N G Seidah; M Chrétien
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

4.  cDNA structure of the mouse and rat subtilisin/kexin-like PC5: a candidate proprotein convertase expressed in endocrine and nonendocrine cells.

Authors:  J Lusson; D Vieau; J Hamelin; R Day; M Chrétien; N G Seidah
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

5.  The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM).

Authors:  E Decroly; M Vandenbranden; J M Ruysschaert; J Cogniaux; G S Jacob; S C Howard; G Marshall; A Kompelli; A Basak; F Jean
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

6.  Downregulation of prohormone convertase-1 by a phorbol ester.

Authors:  V Udupi; C M Townsend; G Gomez; T Zhang; G H Greeley
Journal:  Biochem Biophys Res Commun       Date:  1995-12-14       Impact factor: 3.575

7.  Characterization of the endopeptidase PC2 activity towards secretogranin II in stably transfected PC12 cells.

Authors:  A S Dittié; S A Tooze
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

8.  Ontogeny of the prohormone convertases PC1 and PC2 in the mouse hypophysis and their colocalization with corticotropin and alpha-melanotropin.

Authors:  M Marcinkiewicz; R Day; N G Seidah; M Chrétien
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Testicular expression of PC4 in the rat: molecular diversity of a novel germ cell-specific Kex2/subtilisin-like proprotein convertase.

Authors:  N G Seidah; R Day; J Hamelin; A Gaspar; M W Collard; M Chrétien
Journal:  Mol Endocrinol       Date:  1992-10

Review 10.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

View more
  13 in total

1.  On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.

Authors:  Frédéric Couture; François D'Anjou; Robert Day
Journal:  Biomol Concepts       Date:  2011-10-01

Review 2.  Melanotrope cells as a model to understand the (patho)physiological regulation of hormone secretion.

Authors:  R Vàzquez-Martínez; J R Peinado; D Cruz-García; A Ruiz-Navarro; F Gracia-Navarro; Y Anouar; M C Tonon; H Vaudry; J P Castaño; M M Malagón
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

3.  Chromogranin A transcription and gene expression in Folliculostellate (TtT/GF) cells inhibit cell growth.

Authors:  Gail A Stilling; Jill M Bayliss; Long Jin; Heyu Zhang; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  Galectin-4 expression in carcinoid tumors.

Authors:  Kandelaria M Rumilla; Lori A Erickson; Alan K Erickson; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 5.  Role of subtilisin-like convertases in cadherin processing or the conundrum to stall cadherin function by convertase inhibitors in cancer therapy.

Authors:  E J Müller; R Caldelari; H Posthaus
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

6.  Regulation of VEGF-A, VEGFR-I, thrombospondin-1, -2, and -3 expression in a human pituitary cell line (HP75) by TGFbeta1, bFGF, and EGF.

Authors:  Hidehisa Horiguchi; Long Jin; Katharina H Ruebel; Bernd W Scheithauer; Ricardo V Lloyd
Journal:  Endocrine       Date:  2004-07       Impact factor: 3.633

7.  Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.

Authors:  Long Jin; Shuya Zhang; Jill Bayliss; Bernd Scheithauer; Xiang Qian; Ikuo Kobayashi; Mats Stridsberg; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 8.  Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy.

Authors:  Abdel-Majid Khatib; Géraldine Siegfried; Michel Chrétien; Peter Metrakos; Nabil G Seidah
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

9.  Regulation of cell growth and expression of 7B2, PC2, and PC1/3 by TGFbeta 1 and sodium butyrate in a human pituitary cell line (HP75).

Authors:  Ikuo Kobayashi; Long Jin; Katharina H Ruebel; Jill M Bayliss; Oka Hidehiro; Ricardo V Lloyd
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

10.  Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.

Authors:  Kazumi Iino; Yutaka Oki; Fumie Matsushita; Miho Yamashita; Chiga Hayashi; Katsutoshi Miura; Shigeru Nishizawa; Hirotoshi Nakamura
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.